ALS Texas

  • Understanding ALS
    • ALS Symptoms
    • Stages of ALS
    • What Causes ALS?
    • Lou Gehrig and the History of ALS
    • ALS Glossary
  • Who We Are
    • What We Do
    • Our Leadership
    • Financial Information
    • Our Partners
    • Careers
  • Research
    • How ALS Patients Can Help
    • Research Resources
    • Research News
    • ALS Association Research
  • Navigating ALS
    • Newly Diagnosed
      • What Do I Do Now?
      • How to Share Your Diagnosis
      • Second Opinions
      • Resources
      • Clinics and Centers
    • Living with ALS
      • For Patients
      • Therapies & Care
        • Nutrition & Feeding Tubes
        • How to Improve Mobility
        • Dealing with Breathing Issues
        • Dealing with Speech & Swallowing Issues
        • Types of Assistive Equipment & Technology
        • Clinics and Centers
      • Living Setting
      • Daily Living Activities
      • Leisure Activities
      • Accessible Vehicles
      • More in Depth Resources/Manuals
    • Coping with ALS
      • Dealing with Anxiety/Depression
      • Changes in Thinking & Emotional Lability
      • Support Groups
      • Resources
    • For Caregivers
      • Caregiver Program
      • Caregiver Resources
      • Practicing Self Care
      • From One Caregiver To Another
    • For Youth & Children
    • Virtual Support Groups & Workshops
      • Past Virtual Event Recordings
    • Resources
      • Healthcare/Insurance
      • Hospice & Palliative Care
      • Finances/Employment
      • Taxes
      • Advance Directives
      • More in Depth Resources/Manuals
      • Register with ALS Texas
  • Get Involved
    • Walk to Defeat ALS®
      • Register for a Walk
    • Texas Chapter Events
      • Houston Marathon and Half Marathon
      • All In For ALS Poker Tournament
      • Sporting Clay Shoot
      • Under Ballou Skies Golf Classic and Party
      • ALS Fishing Classic
      • The Cowtown Affair
    • Calendar of Events
    • Fundraising Opportunities
    • Ways to Give
      • Corporate Partnerships
      • Workplace Giving
      • Community Giving Programs
    • Volunteer
    • The ALS Ice Bucket Challenge
  • Advocate
    • Advocacy Day
    • Advocacy News
  • Contact Us
Menu
  • Understanding ALS
    • ALS Symptoms
    • Stages of ALS
    • What Causes ALS?
    • Lou Gehrig and the History of ALS
    • ALS Glossary
  • Who We Are
    • What We Do
    • Our Leadership
    • Financial Information
    • Our Partners
    • Careers
  • Research
    • How ALS Patients Can Help
    • Research Resources
    • Research News
    • ALS Association Research
  • Navigating ALS
    • Newly Diagnosed
      • What Do I Do Now?
      • How to Share Your Diagnosis
      • Second Opinions
      • Resources
      • Clinics and Centers
    • Living with ALS
      • For Patients
      • Therapies & Care
        • Nutrition & Feeding Tubes
        • How to Improve Mobility
        • Dealing with Breathing Issues
        • Dealing with Speech & Swallowing Issues
        • Types of Assistive Equipment & Technology
        • Clinics and Centers
      • Living Setting
      • Daily Living Activities
      • Leisure Activities
      • Accessible Vehicles
      • More in Depth Resources/Manuals
    • Coping with ALS
      • Dealing with Anxiety/Depression
      • Changes in Thinking & Emotional Lability
      • Support Groups
      • Resources
    • For Caregivers
      • Caregiver Program
      • Caregiver Resources
      • Practicing Self Care
      • From One Caregiver To Another
    • For Youth & Children
    • Virtual Support Groups & Workshops
      • Past Virtual Event Recordings
    • Resources
      • Healthcare/Insurance
      • Hospice & Palliative Care
      • Finances/Employment
      • Taxes
      • Advance Directives
      • More in Depth Resources/Manuals
      • Register with ALS Texas
  • Get Involved
    • Walk to Defeat ALS®
      • Register for a Walk
    • Texas Chapter Events
      • Houston Marathon and Half Marathon
      • All In For ALS Poker Tournament
      • Sporting Clay Shoot
      • Under Ballou Skies Golf Classic and Party
      • ALS Fishing Classic
      • The Cowtown Affair
    • Calendar of Events
    • Fundraising Opportunities
    • Ways to Give
      • Corporate Partnerships
      • Workplace Giving
      • Community Giving Programs
    • Volunteer
    • The ALS Ice Bucket Challenge
  • Advocate
    • Advocacy Day
    • Advocacy News
  • Contact Us
  • DONATE
Menu
  • DONATE
Donate

ALS Association Awards Joint Grant to Help Fund Houston Neurologist’s Groundbreaking Research

November 5, 2019 by Jacque Amadi Leave a Comment

The ALS Association, ALS Finding a Cure (ALSFAC), and MDA have jointly awarded a $2.5 million clinical trial grant to Dr. Stanley Appel and his team of researchers at the Houston Methodist Neurological Institute, and Dr. Merit Cudkowicz and his team at Massachusetts General Hospital.

The funding award will allow Dr. Appel to expand the first-in-human study that demonstrated promising results leveraging patients’ own immune cells to treat ALS. [Read more…]

Filed Under: Research

Houston Neurologist Discovers Treatment That Could Halt the Progression of ALS

June 28, 2019 by Jacque Amadi 65 Comments

Research Study Information and Photos Provided by Methodist Houston Hospital

Dr. Stanley Appel, neurologist and co-director of the Houston Methodist Hospital Neurology Institute, has been leading the ALS Clinic at Houston Methodist Hospital since its founding in 1982. This was the first multi-disciplinary clinic dedicated to the treatment of and research on ALS. More than 35 years later, he continues to innovate in the field.

His latest research? An immunotherapy treatment that could stop the progression of ALS in its tracks. [Read more…]

Filed Under: Research, Research News

Closer to a Cure: Researchers Open Enrollment for Tofersen Phase 3 Clinical Trial

May 17, 2019 by Jacque Amadi 2 Comments

Our “closer to a cure” segment will highlight research news and important milestones made by researchers as they work towards finding a cure for ALS.

Exciting news! Neuroscience collective Biogen has initiated a phase 3 clinical trial to evaluate Tofersen (previously called BIIB067), a type of antisense drug meant to target superoxide dismutase (SOD1), for the potential treatment of ALS. 

It’s approximated that two percent of people living with ALS have a mutation in the SOD1 gene- the second most common cause of genetic ALS. An SOD1 mutation leads to abnormal protein, which is likely toxic to cells and could lead to the death of motor neurons- the cells that die in ALS. Tofersen has been designed to reduce levels of SOD1 protein in people with ALS caused by an SOD1 gene mutation.

The trial is currently enrolling with 60 spots available for people with SOD1 ALS.

Interested in enrolling and helping researchers test the safety and efficacy of Tofersen? The ALS Association has worked with Biogen to create a FAQ surrounding the trial. The FAQ covers how to enroll, where to get more information, study design and endpoints, expanded access, and more. See the FAQ here.

For more information about the clinical trial and its currently enrolling locations, visit: https://clinicaltrials.gov/ct2/show/NCT02623699.

Filed Under: Research, Research News

Closer to a Cure: What is the KIF5A ALS gene & why is it important

April 9, 2019 by Jacque Amadi 1 Comment

Our “closer to a cure” segment will highlight research news and important milestones made by researchers as they work towards finding a cure for ALS.

While ALS is currently a disease with no cure and limited treatment options, the ALS Association continues to fund groundbreaking research to bring us closer to a cure. Last March, researchers from collaborative initiatives funded by The ALS Association, with money raised through the ALS Ice Bucket Challenge, announced the discovery of a new ALS gene- KIF5A.

You may have heard the news in the past year, but do you truly understand what the KIF5A gene is and why it’s important? If your answer is “no” that’s ok! That’s what we’re here for.

What is the KIF5A ALS Gene?

The KIF5A ALS gene was discovered through a unique collaborative effort of over 250 researchers, led by Dr. John Landers at University of Massachusetts Medical School and Dr. Bryan Traynor at the NIH. Researchers analyzed genetic data from over 101,000 samples to discover the KIF5A gene and it’s actually the fifth new ALS gene discovered since the 2014 Ice Bucket Challenge.

KIF5A, or kinesin family member 5A, is a motor protein involved in the protein cargo transportation in cells. Kinesins play an important role in transporting along a motor neuron axon, which is crucial to motor neuron health. Mutations identified in KIF5A may cause disease by interrupting that axonal transport.

Why is the KIF5A ALS Gene Important?

Identifying common pathways leading to ALS is an important part of creating new treatments to slow or reverse the progression of ALS. The more we understand about the mechanics of the disease, the closer we get to finding a cure.

ALS is a disease that’s incurable for now, but with more research we have hope that a cure will be discovered.

Filed Under: Research, Research News

Serving in the Military Poses 60% Higher Risk for ALS

March 21, 2019 by Jacque Amadi 1 Comment

For decades, researchers have been searching for correlations that may give insight into what causes ALS. While the direct cause remains elusive, there have been interesting findings over the years that could possibly bring us closer to a cure.

The ALS Association has released a new report highlighting the prevalence of ALS among military service members. In the 2019 ALS in the Military report, it was found that those who have served in the military are at a nearly 60% greater risk of developing ALS than those who have no history of military service. In addition, the data shows that ALS is connected to military service regardless of the branch of service or whether serving during peacetime or in war.

The report compiled findings from research conducted from the early 1990’s up until recent years with one of these studies examining  military members going back as far as 1910.  Finally in 2008, after many studies and decades of research,  the Department of Veterans Affairs established ALS as a service-connected disease. Since then, the average number of veterans living with ALS has increased by a staggering 30 percent.

“Study after study has shown that our military heroes are more likely to develop ALS, which is why it is critical that Congress fully funds the ALS Research Program at the Department of Defense, as well as research at the National Institutes of Health,” said Calaneet Balas, president and CEO of The ALS Association.

We’ve made strides and progress but we need more support to fund research that could help both veterans and non-veterans alike. ALS is a devastating disease but with your help, we’re well on our way to a deeper understanding and possibility of a cure.

Filed Under: News, Research, Research News

ALS Association Awards $1 Million to Fund Potential ALS Treatment

November 28, 2018 by Jacque Amadi 2 Comments

Today marks a monumental day for ALS research as the first in-human clinical trials of AT-1501 have begun. AT-1501 is an antibody therapeutic developed by the ALS Therapy Development Institute (ALS TDI), with support from The ALS Association, ALS ONE, and ALS Finding a Cure®. The drug blocks immune cell activation and protects nerves against the progression of ALS. As of today researchers at Anelixis Therapeutics, lead by Dr. Steve Perrin, have successfully administered a dose of AT-1501 to the study’s first participant.

This is a great progressive step on our journey for a cure, and we’re happy to announce that the ALS Association awarded an additional $1 million to Anelixis to help fund this groundbreaking research.

“We are proud to partner with Anelixis and other ALS organizations to help advance this promising compound into clinical trials,” said Calaneet Balas, President and CEO of The ALS Association.

The safety trial of this potentially new treatment is currently enrolling volunteers, both those with ALS and those without, to participate in the study. In total, eight people with ALS will receive AT-1501 and will be monitored for safety , tolerability, and how the drug moves through the body. If it’s proven safe the trial will then move on to Phase II.

We’re excited for the prospect of this new treatment and we remain hopeful that together with patients, caretakers, donors, and researchers we can create a world without ALS.

Help us create a world without ALS by donating today.

Filed Under: Research, Research News Tagged With: news, Research, research news

“Spark Hope For a World Without ALS” – Our 2018 Recap

November 27, 2018 by Jacque Amadi Leave a Comment

In 2018 we set out with the goal to spark hope, ignite action, and inspire others to join us in the fight to create a world without ALS. And it was thanks to our wonderful community that we were able to achieve that goal. Throughout the year we provided patient services, hosted community events, and helped fund life-changing research to find new treatments for this devastating disease.

[Read more…]

Filed Under: Fundraising, Research Tagged With: ALS News, ALS Research, ALS Texas, fundraising, walk to defeat als

Dodgeball Tournament Raises Over $55,000 in Three Years to Support ALS Research

June 27, 2017 by Elise Bernard 1 Comment

ALS dodgeball tournament hosts

Three days before Christmas 2009, Turner Corbett’s family got the devastating news that his mom, Jennifer, had been diagnosed with ALS. Turner was just 12 years old.

Wanting to make the most of a difficult situation, in 2015, Turner created a benefit event that would raise money for ALS research. After running through some ideas with his friend Alex Doswell, they decided a dodgeball tournament would be the most fun and family friendly.

[Read more…]

Filed Under: Fundraising, Research Tagged With: advocacy, als, ALS awareness, ALS Research, als stories, ALS Texas, fundraising, pals, Research

Frequently Asked Questions about Radicava™ (Edaravone)

May 6, 2017 by Tanner Hockensmith 21 Comments

Based on information as of 5/5/2017

What is Radicava?

Radicava™ (edaravone) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) to treat people with amyotrophic lateral sclerosis (ALS).1

In clinical trials, some people given Radicava showed significantly less decline in physical function compared to placebo as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R), a validated rating instrument for monitoring the progression of disability in patients with ALS.1,2

[Read more…]

Filed Under: Research, Research News Tagged With: als, ALS drug, ALS News, ALS Research, ALS Research Update, ALS treatment, FDA, Research, research news

FDA Approves New ALS Drug

May 5, 2017 by Tanner Hockensmith 3 Comments

Radicava is First Approved Treatment for ALS in Decades

The Food and Drug Administration’s (FDA) announced today that it has approved Radicava (edaravone), the first new treatment approved specifically for ALS in 22 years. The FDA approved Radicava less than a year after Mitsubishi Tanabe Pharma Corporation submitted a New Drug Application. The only other approved treatment specifically for ALS, riluzole, was approved in 1995.

“We thank the FDA and MT Pharma for working together to expedite the approval of the first new ALS-specific treatment in decades,” said Barbara Newhouse, president and CEO of The ALS Association. “We hope today’s announcement signals the beginning of a new chapter in the fight against this terrible disease. There are several drugs to treat ALS currently in clinical trials and we are hopeful that people living with ALS have even more therapies available to them sooner rather than later.”

[Read more…]

Filed Under: Research, Research News Tagged With: als, ALS drug, ALS News, ALS Research, ALS Research Update, ALS treatment, FDA, national als advocacy day, Research, research news

  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
  • Site Map
  • Privacy Policy
  • Link Policy
  • Contact Us

The ALS Association of Texas | 877.714.0088
All content and works posted on this website are owned and copyrighted by the ALS Association of Texas © 2021


Dallas Office 14555 Dallas Parkway Suite 100-219, Dallas, Texas 75254
San Antonio Office We're working from home! Please send mail to the Dallas office.
Austin Office 2301 W Anderson Lane, Austin, TX, 78757
Houston Office 4201 Main Street, Suite 200-142, Houston, TX 77002